Open Access

ARTICLE

GABPB1-AS1 acts as a tumor suppressor and inhibits non-small cell lung cancer progression by targeting miRNA-566/F-box protein 47

by HUALIANG LV^1,#,*, CHANGCHUN LAI^2,#, WENQU ZHAO³, YIBO SONG¹

1 Department of Pulmonary and Critical Care Medicine, Maoming People’s Hospital, Maoming, China
2 Department of Clinical Laboratory, Maoming People’s Hospital, Maoming, China
3 Department of Pulmonary and Critical Care Medicine, Nanfang Hospital Affiliated to Southern Medical University, Guangzhou, China

* Corresponding Author: HUALIANG LV. Email:
# Equal contributor

Oncology Research 2021, 29(6), 401-409. https://doi.org/10.32604/or.2022.025262

Received 02 July 2022; Accepted 25 September 2022; Issue published 10 November 2022

Abstract

It has been certified that GABPB1-AS1 is aberrantly expressed and plays as a vital role in some kinds of cancers. However, its expression pattern and functions in non-small cell lung cancer (NSCLC) are still largely unknown. This study aims to assess GABPB1-AS1 expression and biological roles in NSCLC. The expression of GABPB1-AS1 was detected in NSCLC specimens and adjacent normal specimens. CCK8 and Transwell assays were performed to evaluate the effects of GABPB1-AS1 on NSCLC cell proliferation, migration and invasion. Bioinformatics tools and luciferase reporter assays were applied to predict and verify GABPB1-AS1’s direct targets. The results revealed that GABPB1-AS1 is sharply reduced in NSCLC specimens and cell lines. CCK8 assays indicated that overexpression of GABPB1-AS1 dramatically reduced NSCLC cell growth, and Transwell assays proved that NSCLC cell migration and invasion were distinctly inhibited by GABPB1-AS1. Exploration of the mechanism uncovered that miRNA-566 (miR-566)/F-box protein 47 (FBXO47) is directly targeted by GABPB1-AS1 in NSCLC. The study demonstrated that GABPB1-AS1 inhibited NSCLC cell proliferation, migration and invasion by targeting miR-566/FBXO47.

---

Keywords

---